Blood Coagulation Testing Market Research Report Information by Product (Consumables and Instruments), by Application (Acquired Bleeding Disorders and Inherited Bleeding Disorders), by Test Type (Prothrombin Time Testing, Activated Partial Thromboplastin Time (aPTT) Testing, Fibrinogen Testing, Activated Clotting Time Testing, Platelet Function Tests, and Others), by End User (Hospitals and Clinics, Diagnostic Centers, Ambulatory Care Centers, and Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World - Forecast

Blood Coagulation Testing Market Overview

Blood Coagulation Testing Market size was valued at USD 4.51 billion in 2023. The Blood Coagulation Testing Market industry is projected to grow from USD 4.81 billion in 2024 to USD 7.84 billion by 2032.This exhibits a compound annual growth rate (CAGR) of 6.31% during the forecast period (2024 - 2032). The increasing incidences of blood-acquired bleeding disorders are major factors driving growth.

Rising product launches by market players in the blood coagulation testing market also contribute significantly. However, voluntary product recalls by market players and high costs associated with coagulation analyzers are expected to hamper growth.

Nevertheless, favorable government initiatives related to bleeding disorders are anticipated to create lucrative opportunities. A growing geriatric population across the globe will also positively impact the market.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Blood Coagulation Testing Trends

Increasing incidences of blood acquired bleeding disorders fuels market growth

The growing incidence of both acquired and inherited bleeding disorders, including hemophilia and von Willebrand Disease, is significantly driving market expansion. As the prevalence of these disorders increases, demand for advanced coagulation tests rises.

This increase is due to heightened awareness and better diagnostic capabilities. Inherited conditions like hemophilia and von Willebrand Disease are now more frequently identified and managed.

Acquired bleeding disorders also contribute to a greater need for precise testing. For instance, the Centers for Disease Control and Prevention reported Von Willebrand disease (VWD) affects approximately 1% of the general population.

There is no significant difference in frequency between men and women. However, women are more prone to experiencing VWD symptoms due to increased bleeding during menstrual periods, pregnancy, and childbirth.

From 2012 to 2023, over 33,456 individuals, including men, women, and children, sought treatment for VWD at hemophilia treatment centers. Moreover, in 2024, Pfizer, Inc. (US) stated that globally, over 200,000 individuals are known to have some form of hemophilia.

Recent data suggest the true number may be significantly higher, potentially exceeding 1.1 million. In the United States, estimates indicate approximately 33,000 individuals assigned male at birth are living with the condition.

Moreover, as per the World Federation for Hemophilia in 2020, there were 209,614 people with hemophilia worldwide. This included 165,379 with Hemophilia A, 33,076 with Hemophilia B, and 11,159 with Hemophilia type unknown.

Additionally, 84,197 had von Willebrand disease and 53,215 had other bleeding disorders.

Blood Coagulation Testing Segment Insights

Blood Coagulation Testing Product Insights

The Blood Coagulation Testing Market segmentation, based on product, includes consumables and instruments. The consumables segment held the largest market in 2023.

The instruments segment is the fastest growing segment during the forecast period. A rise in surgical procedures globally, particularly those involving cardiovascular systems, requires pre-operative and post-operative coagulation testing.

The introduction of new and improved blood coagulation testing consumables, along with regulatory approvals, is driving market growth. These offer more accurate and reliable testing options.

Blood Coagulation Testing Application Insights

The Blood Coagulation Testing Market segmentation, based on application, includes acquired bleeding disorders and inherited bleeding disorders. The acquired bleeding disorder segment held the largest market share in 2023.

It is also the fastest-growing segment during the forecast period. Increased awareness of the risks associated with acquired bleeding disorders, particularly among patients on long-term anticoagulant therapy, has led to more frequent monitoring and testing.

Figure 2: Blood Coagulation Testing Market, by Application, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Blood Coagulation Testing Test Type Insights

The Blood Coagulation Testing Market segmentation, based on test type, includes prothrombin time testing and activated partial thromboplastin time (aPTT) testing. Other types are fibrinogen testing, activated clotting time testing, platelet function tests, and others.

The prothrombin time testing segment held the largest market in 2023. The activated partial thromboplastin time (aPTT) testing segment is the fastest growing segment.

The growing number of people suffering from Vitamin K deficiency, liver disease, and bleeding disorders such as hemophilia is driving up demand for PT testing. Furthermore, PT is important in controlling warfarin therapy.

It helps assess the anticoagulant's effectiveness and prevent problems such as excessive bleeding or clot formation.

The Blood Coagulation Testing Market segmentation, based on end user, includes hospitals and clinics, diagnostic centers, and ambulatory care centers. Other end users are also included.

The hospitals and clinics segment held the largest market in 2023. The diagnostic centers segment is the fastest growing segment during the forecast period.

Growth of healthcare infrastructure, including new hospitals and clinics, particularly in emerging markets, expands the reach of coagulation testing services. This also increases their availability.

Blood Coagulation Testing Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. The North America Blood Coagulation Testing market is experiencing significant growth.

This growth is driven by factors such as a high incidence of coagulation disorders and advancements in technology and innovation. Furthermore, the region's well-established healthcare infrastructure, technological innovations, and favorable regulatory environment contribute to market expansion.

Further, the major countries to be studied are US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: BLOOD COAGULATION TESTING MARKET BY REGION 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Blood Coagulation Testing market accounted for the second-largest market share due to robust healthcare infrastructure. Supportive government health initiatives and funding also contribute.

Furthermore, the Germany Blood Coagulation Testing provider accounted to hold the largest market share. The France Blood Coagulation Testing providers is projected to be the fastest growing market in the Europe region.

The Asia-Pacific Blood Coagulation Testing market is expected to be the fastest growing from 2023 to 2032. This is due to growing awareness of health management and early diagnosis among the population.

Favorable reimbursement policies for coagulation tests also play a role. Moreover, China Blood Coagulation Testing accounted to hold the largest market share.

The India Blood Coagulation Testing is projected to be the fastest growing market in the Asia-Pacific region.

Blood Coagulation Testing Key Market Players & Competitive Insights

The Blood Coagulation Testing Market is distinguished by the presence of numerous regional and local players. These cater to the Blood Coagulation Testing Market.

Furthermore, increasing incidences of blood-acquired bleeding disorders are major factors driving growth. Rising product launches by market players in blood coagulation testing also contribute significantly.

Moreover, the rising Point-of-care (POC) testing solutions is also contributing as a significant growth driver for the market.

Hoffmann-La Roche Ltd (Roche) is one of the leading companies in the field of diagnostics and pharmaceuticals. It develops and markets products for diagnosis and treatment of anemia, cancer, and anticoagulation therapy.

Other areas include cardiovascular diseases, diabetes, central nervous system, chlamydia, dermatology, gonorrhea, gout, hepatitis B and C, hemostasis disorders, HIV/AIDS, HPV, infectious diseases, and autoimmune diseases. The company specializes in molecular diagnostics and medicines for oncology, virology, and inflammation.

Metabolism, central nervous system, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology are also areas of focus. The firm operates in two major business segments Pharmaceuticals and Diagnostics.

The Pharmaceuticals segment offers a wide range of drugs for therapeutic areas, such as oncology, inflammation, neuroscience, infectious diseases, and ophthalmology. This segment focuses on transforming scientific excellence into effective patient treatments.

By integrating pioneering research conducted at Roche, Genentech in the US, Chugai in Japan, and collaborating with over 250 partners globally. Roche leverages its extensive capabilities in clinical development, manufacturing, and commercial operations on a global scale.

The diagnostics segment offers a wide range of tests for cancer and companion diagnostic tests. In over 100 countries, they provide the industry’s most extensive in vitro diagnostics testing portfolio.

This is enhanced by clinical decision support, consultancy services, digital diagnostics, disease management, laboratory automation, and software solutions. These offerings deliver integrated solutions for laboratories, clinicians, and healthcare systems.

Additionally, their autonomous research and development centers, along with alliances with over 250 external partners. These promote a diverse range of scientific approaches and ensure agility in innovation.

The company has a strong presence in North America, Europe, Asia, and the Middle East. The company distributes its products globally.

Moreover, in February 2024, Roche introduced three new coagulation tests for oral Factor Xa inhibitors. These included apixaban, edoxaban, and rivaroxaban in CE-mark-accepting countries.

These tests are designed to aid clinical decision-making for patients using direct oral anticoagulants. They help in managing conditions such as non-valvular atrial fibrillation, coronary artery disease, peripheral arterial disease, and venous thromboembolism.

Key Companies in the Blood Coagulation Testing market include

• Hoffmann-La Roche Ltd.


• Abbott


• Siemens Healthcare


• Thermo Fisher Scientific Inc.


• Sysmex Corporation


• Werfen


• HemoSonics, LLC


• Micropoint Biotechnologies Co., Ltd.


• Helena Laboratories


• Meril Life Sciences Pvt. Ltd.

Blood Coagulation Testing Industry Developments

• 
  
  
  
  • In July 2024, Roche completed the acquisition of LumiraDx’s Point of Care technology. This transformative solution will enhance Roche’s diagnostics portfolio. It will integrate with their existing capabilities in Clinical Chemistry, Immunochemistry, Coagulation, and Molecular diagnostics across various disease areas.
  
  
  
  


• In April 2024, Sysmex Europe SE announced the opening of a new branch office, Sysmex Nordic ApS, in Finland. Sysmex aims to improve its market presence by increasing its sales and support network in the region.


• In February 2024, HemoSonics, LLC, announced that its Quantra Hemostasis System with QPlus and QStat Cartridges has been selected as a finalist in the 2024 Edison™ Awards. The company received this recognition in the health, medical, and biotechnology category for its Quantra Hemostasis System.

Blood Coagulation Testing Segmentation

Blood Coagulation Testing Product Outlook

• Consumables




• Reagents


• Test Kits




• Instruments

Blood Coagulation Testing Application Outlook

• Acquired Bleeding Disorders


• Inherited Bleeding Disorders




• Hemophilia


• Von Willebrand Disease


• Others

Blood Coagulation Testing Test Type Outlook

• Prothrombin Time Testing


• Activated Partial Thromboplastin Time (aPTT) Testing


• Fibrinogen Testing


• Activated Clotting Time Testing


• Platelet Function Tests


• Others

Blood Coagulation Testing End User Outlook

• Hospitals and Clinics


• Diagnostic Centers


• Ambulatory Care Centers


• Others

Blood Coagulation Testing Regional Outlook

• North America




• US


• Canada




• Europe




• Germany


• France


• UK


• Italy


• Spain


• Rest of Europe




• Asia-Pacific




• China


• Japan


• India


• South Korea


• Australia


• Rest of Asia-Pacific




• Rest of the World




• Middle East


• Africa


• Latin America

Attribute/Metric	Details
Market Size 2023	USD 4.51 billion
Market Size 2024	USD 4.81 billion
Market Size 2032	USD 7.84 billion
Compound Annual Growth Rate (CAGR)	6.31% (2024-2032)
Base Year	2023
Forecast Period	2024-2032
Historical Data	2019 to 2022
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Product, application, test type, end user, and Region
Geographies Covered	North America, Europe, Asia Pacific, and Rest of the World
Countries Covered	The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled	·       F. Hoffmann-La Roche Ltd. ·       Abbott ·       Siemens Healthcare ·       Thermo Fisher Scientific Inc. ·       Sysmex Corporation ·       Werfen ·       HemoSonics, LLC ·       Micropoint Biotechnologies Co., Ltd. ·       Helena Laboratories ·       Meril Life Sciences Pvt. Ltd.
Key Market Opportunities	·       Favorable government initiatives associated with bleeding disorders ·       Growing geriatric population across the globe
Key Market Drivers	·       Increasing incidences of blood acquired bleeding disorders ·       Rising product launches by market player